Cosmo Pharmaceuticals N.V. provided earnings guidance for the full year of 2018. The company is projecting Aries U.S. between EUR 18 million and EUR 28 million. They expect to have revenues between EUR 84 million and EUR 94 million in 2018. And they expect to have significant operating expenses because the total of the budgeted operating expenses is EUR 125 million, of which EUR 78 million will be spent in Aries, which turns into an expected result between EUR 41 million and 31 million loss.